AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18087270 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth weight <2500 g (exposed)
Number of subjects: 709
Study 18087270 — intervention group
Group type: EXPERIMENTAL
Intervention: Birth weight >=3860 g (highest quartile)
Number of subjects: 709
Study 16565792 — intervention group
Group type: EXPERIMENTAL
Intervention: Heparin for 24 hours combined with 325 mg acetyl‐acetic acid (Group A)
Number of subjects: 100
Study 16565792 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 mg ticlopidine twice a day combined with 325 mg acetyl‐acetic acid (Group B)
Number of subjects: 100
Study 12673611 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-session in-home caregiver training program (experimental group, n = 24)
Number of subjects: 48
Study 12673611 — intervention group
Group type: COMPARATOR
Intervention: Written educational materials (control group, n = 24)
Number of subjects: 48
Study 11048358 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up rates of 60%
Number of subjects: 0
Study 11048358 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up rates of 90-100%
Number of subjects: 0
Study 11048358 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline characteristics (age)
Number of subjects: 0
Study 11048358 — intervention group
Group type: EXPERIMENTAL
Intervention: Follow-up rates below 70%
Number of subjects: 0
Study 8970140 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ferric sodium citrate
Number of subjects: 8
Study 8970140 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ferric sodium citrate with 200 mg ascorbic acid
Number of subjects: 8
Study 8970140 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 mg ferric sodium citrate with physical exercise
Number of subjects: 8
Study 8970140 — intervention group
Group type: COMPARATOR
Intervention: 100 mg ferric sodium citrate without vitamin C
Number of subjects: 8
Study 1468743 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral bacterial lysate
Number of subjects: 620
Study 6204149 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow release potassium tablets (64 mmol/day)
Number of subjects: 23
Study 6204149 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow release potassium tablets (98 mmol/day)
Number of subjects: 23
Study 6204149 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 31434466 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated central venous pressure (CVP)
Number of subjects: 25
Study 31434466 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive end-expiratory pressure (PEEP)
Number of subjects: 25
Study 31434466 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated airway pressure
Number of subjects: 25
Study 31434466 — intervention group
Group type: EXPERIMENTAL
Intervention: Accumulated fluid balance
Number of subjects: 25
Study 31434466 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated SOFA score
Number of subjects: 25
Study 31434466 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction of acidosis
Number of subjects: 25
Study 31434466 — intervention group
Group type: EXPERIMENTAL
Intervention: Increase of serum bicarbonate
Number of subjects: 25
Study 29924507 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate once-monthly (PP1M)
Number of subjects: 133
Study 29924507 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 133
Study 27371719 — intervention group
Group type: EXPERIMENTAL
Intervention: Perindopril 10 mg
Number of subjects: 224
Study 27371719 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 224
Study 27371719 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 224
Study 25453520 — intervention group
Group type: EXPERIMENTAL
Intervention: Footbath at 41°C for 15 minutes
Number of subjects: 22
Study 22670846 — intervention group
Group type: EXPERIMENTAL
Intervention: Airtraq laryngoscope
Number of subjects: 132
Study 22670846 — intervention group
Group type: COMPARATOR
Intervention: Macintosh laryngoscope
Number of subjects: 132
Study 20619139 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxibustion
Number of subjects: 65
Study 20619139 — intervention group
Group type: COMPARATOR
Intervention: Western medicine
Number of subjects: 65
Study 17293760 — intervention group
Group type: EXPERIMENTAL
Intervention: Team-centered curriculum
Number of subjects: 599
Study 17293760 — intervention group
Group type: EXPERIMENTAL
Intervention: One-on-one motivational interviewing (MI)
Number of subjects: 599
Study 17293760 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 599
Study 15585567 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (beta-adrenergic blocker)
Number of subjects: 42
Study 15585567 — intervention group
Group type: EXPERIMENTAL
Intervention: Metyrapone (corticosteroid synthesis inhibitor)
Number of subjects: 42
Study 15585567 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study 12013162 — intervention group
Group type: EXPERIMENTAL
Intervention: 22-item questionnaire
Number of subjects: 630
Study 10468758 — intervention group
Group type: EXPERIMENTAL
Intervention: Absorbable (polyglyconate) staples
Number of subjects: 50
Study 10468758 — intervention group
Group type: COMPARATOR
Intervention: Nonabsorbable (metal) staples
Number of subjects: 50
Study 7782111 — intervention group
Group type: EXPERIMENTAL
Intervention: Roxithromycin
Number of subjects: 242
Study 7782111 — intervention group
Group type: COMPARATOR
Intervention: Amoxycillin/clavulanic acid
Number of subjects: 242
Study 7782111 — intervention group
Group type: EXPERIMENTAL
Intervention: Cost-effectiveness of Roxithromycin
Number of subjects: 242
Study 2351709 — intervention group
Group type: EXPERIMENTAL
Intervention: Dydrogesterone three times daily (TID) beginning on the day of embryo transfer (ET)
Number of subjects: 156
Study 2351709 — intervention group
Group type: EXPERIMENTAL
Intervention: HCG on days 3, 6 and 10 following ET
Number of subjects: 156
Study 2351709 — intervention group
Group type: COMPARATOR
Intervention: Placebo p.o. TID beginning on the day of ET
Number of subjects: 156
Study 400187 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative radiotherapy
Number of subjects: 650
Study 400187 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy, immunotherapy, immunochemotherapy, and observation
Number of subjects: 650
Study 31682584 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartphone-based approach-avoidance intervention (n=35)
Number of subjects: 105
Study 31682584 — intervention group
Group type: COMPARATOR
Intervention: Placebo control group (n=35)
Number of subjects: 105
Study 31682584 — intervention group
Group type: COMPARATOR
Intervention: Inactive control group (n=35)
Number of subjects: 105
Study 31682584 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (experimental, placebo, inactive)
Number of subjects: 105
Study 29306231 — intervention group
Group type: EXPERIMENTAL
Intervention: Local autograft with allograft
Number of subjects: 65
Study 29306231 — intervention group
Group type: EXPERIMENTAL
Intervention: Local autograft only
Number of subjects: 65
Study 29306231 — intervention group
Group type: EXPERIMENTAL
Intervention: Local autograft and posterior iliac crest autograft
Number of subjects: 65
Study 29306231 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 65
Study 25542273 — intervention group
Group type: EXPERIMENTAL
Intervention: Autonomy-supportive interpersonal style
Number of subjects: 705
Study 25542273 — intervention group
Group type: COMPARATOR
Intervention: Controlling interpersonal style
Number of subjects: 705
Study 22882381 — intervention group
Group type: EXPERIMENTAL
Intervention: Haemonetics cardioPAT system
Number of subjects: 1047
Study 21299293 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive smoking cessation intervention (C‐STOP)
Number of subjects: 1189
Study 19842242 — intervention group
Group type: EXPERIMENTAL
Intervention: Target-Controlled Infusion (TCI)
Number of subjects: 50
Study 19842242 — intervention group
Group type: COMPARATOR
Intervention: Manually Controlled Infusion (MCI)
Number of subjects: 50
Study 16785477 — intervention group
Group type: EXPERIMENTAL
Intervention: Verapamil sustained-release or atenolol-based strategy
Number of subjects: 22576
Study 16785477 — intervention group
Group type: EXPERIMENTAL
Intervention: Low diastolic blood pressure
Number of subjects: 22576
Study 16785477 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic pressure below 119/84 mm Hg
Number of subjects: 22576
Study 16785477 — intervention group
Group type: EXPERIMENTAL
Intervention: History of revascularization
Number of subjects: 22576
Study 14555255 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 60 mg/day
Number of subjects: 7705
Study 14555255 — intervention group
Group type: EXPERIMENTAL
Intervention: Raloxifene 120 mg/day
Number of subjects: 7705
Study 14555255 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7705
Study 10983646 — intervention group
Group type: EXPERIMENTAL
Intervention: d4T + 3TC + IDV
Number of subjects: 204
Study 10983646 — intervention group
Group type: COMPARATOR
Intervention: ZDV + 3TC + IDV
Number of subjects: 204
Study 9097197 — intervention group
Group type: EXPERIMENTAL
Intervention: Family-state induction
Number of subjects: 64
Study 9097197 — intervention group
Group type: COMPARATOR
Intervention: Neutral-state induction
Number of subjects: 64
Study 8227900 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion at low-dose (0.25 microgram/min)
Number of subjects: 16
Study 8227900 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion at high-dose (2.0 micrograms/min)
Number of subjects: 16
Study 8227900 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion
Number of subjects: 16
Study 3763935 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucagon
Number of subjects: 0
Study 3763935 — intervention group
Group type: COMPARATOR
Intervention: Control (no glucagon)
Number of subjects: 0
Study 28415143 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiorespiratory fitness (CRF) measured by VO2max
Number of subjects: 39
Study 28415143 — intervention group
Group type: EXPERIMENTAL
Intervention: Leisure-time physical activity (LTPA)
Number of subjects: 39
Study 26610389 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile application
Number of subjects: 173
Study 26610389 — intervention group
Group type: COMPARATOR
Intervention: Spiral-notebook guide
Number of subjects: 173
Study 24632572 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA-S
Number of subjects: 60
Study 24632572 — intervention group
Group type: COMPARATOR
Intervention: I-gel
Number of subjects: 60
Study 24632572 — intervention group
Group type: EXPERIMENTAL
Intervention: Both devices
Number of subjects: 60
Study 21538680 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behaviour Therapy (CBT)
Number of subjects: 210
Study 21538680 — intervention group
Group type: COMPARATOR
Intervention: Usual Care
Number of subjects: 210
Study 20534644 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone (LDN)
Number of subjects: 96
Study 20534644 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 96
Study 18773725 — intervention group
Group type: EXPERIMENTAL
Intervention: Correspondence matching in long-range motion
Number of subjects: 0
Study 18773725 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 15001596 — intervention group
Group type: EXPERIMENTAL
Intervention: nurse-monitoring
Number of subjects: 75
Study 15001596 — intervention group
Group type: EXPERIMENTAL
Intervention: marker-monitoring
Number of subjects: 75
Study 15001596 — intervention group
Group type: COMPARATOR
Intervention: no monitoring
Number of subjects: 75
Study 11331169 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyethyl starch (HES)
Number of subjects: 60
Study 11331169 — intervention group
Group type: COMPARATOR
Intervention: Lactated Ringer's solution (LRS)
Number of subjects: 60
Study 11331169 — intervention group
Group type: EXPERIMENTAL
Intervention: HES 200/0.5
Number of subjects: 60
Study 11331169 — intervention group
Group type: EXPERIMENTAL
Intervention: HES groups
Number of subjects: 60
Study 9150068 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 23
Study 9150068 — intervention group
Group type: COMPARATOR
Intervention: D-penicillamine
Number of subjects: 23
Study 7950183 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined therapy of traditional Chinese medicine and Western medicine (TCM-WM)
Number of subjects: 38
Study 7950183 — intervention group
Group type: COMPARATOR
Intervention: Western medicine only (WM)
Number of subjects: 38
Study 3107602 — intervention group
Group type: EXPERIMENTAL
Intervention: lysine acetyl salicylate (LAS) 13 mg kg‐1 i.v. 3 min before suxamethonium
Number of subjects: 20
Study 3107602 — intervention group
Group type: COMPARATOR
Intervention: atracurium 0.09 mg kg‐1
Number of subjects: 20
Study 3107602 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 20
Study 30027568 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehabilitation services
Number of subjects: 0
Study 30027568 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower socioeconomic participants
Number of subjects: 0
Study 30027568 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher socioeconomic participants
Number of subjects: 0
Study 27291448 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 2.5 mg
Number of subjects: 24
Study 27291448 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 5 mg
Number of subjects: 24
Study 27291448 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin 10 mg
Number of subjects: 24
Study 27291448 — intervention group
Group type: EXPERIMENTAL
Intervention: Dapagliflozin (all doses)
Number of subjects: 24
Study 25903109 — intervention group
Group type: EXPERIMENTAL
Intervention: Serelaxin (RELAX group)
Number of subjects: 581
Study 25903109 — intervention group
Group type: COMPARATOR
Intervention: EAHFE-RELAX groups
Number of subjects: 581
Study 23660180 — intervention group
Group type: EXPERIMENTAL
Intervention: IV isotonic sodium bicarbonate
Number of subjects: 8680
Study 23660180 — intervention group
Group type: COMPARATOR
Intervention: IV isotonic sodium chloride
Number of subjects: 8680
Study 23660180 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral N-acetylcysteine (NAC)
Number of subjects: 8680
Study 23660180 — intervention group
Group type: COMPARATOR
Intervention: Oral placebo
Number of subjects: 8680
Study 20950456 — intervention group
Group type: EXPERIMENTAL
Intervention: New DTPw-HBV/Hib vaccine
Number of subjects: 585
Study 20950456 — intervention group
Group type: COMPARATOR
Intervention: Tritanrix™-HBV/Hib (Control)
Number of subjects: 585
Study 18242706 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment of unruptured aneurysms
Number of subjects: 0
Study 18242706 — intervention group
Group type: COMPARATOR
Intervention: Subgroup statistics from observational studies
Number of subjects: 0
Study 18242706 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized trial
Number of subjects: 0
Study 17012640 — intervention group
Group type: EXPERIMENTAL
Intervention: Aussie current
Number of subjects: 32
Study 17012640 — intervention group
Group type: EXPERIMENTAL
Intervention: Russian current
Number of subjects: 32
Study 17012640 — intervention group
Group type: COMPARATOR
Intervention: Monophasic pulsed currents
Number of subjects: 32
Study 14572851 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with healthcare
Number of subjects: 30
Study 14572851 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient satisfaction surveys
Number of subjects: 30
Study 10933737 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent plus abciximab
Number of subjects: 140
Study 10933737 — intervention group
Group type: COMPARATOR
Intervention: Alteplase
Number of subjects: 140
Study 8757567 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO therapy (20 U/kg body weight, subcutaneously, three times a week for 6 weeks)
Number of subjects: 55
Study 8757567 — intervention group
Group type: COMPARATOR
Intervention: Control (sham treatment)
Number of subjects: 55
Study 8757567 — intervention group
Group type: EXPERIMENTAL
Intervention: r‐HuEPO therapy
Number of subjects: 55
Study 8757567 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 55
Study 1424602 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloroform/Methanol (CM) application
Number of subjects: 11
Study 1424602 — intervention group
Group type: COMPARATOR
Intervention: Ether/Acetone (EA) application
Number of subjects: 11
Study 2864775 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate
Number of subjects: 0
Study 2864775 — intervention group
Group type: EXPERIMENTAL
Intervention: Aceclidine
Number of subjects: 0
Study 2864775 — intervention group
Group type: COMPARATOR
Intervention: Timolol and aceclidine combination
Number of subjects: 0
Study 31317553 — intervention group
Group type: EXPERIMENTAL
Intervention: Robotic-assisted therapy with bilateral practice (RTBP)
Number of subjects: 43
Study 31317553 — intervention group
Group type: COMPARATOR
Intervention: Usual task-specific training facilitated by therapists (Control)
Number of subjects: 43
Study 30368373 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapid Maxillary Expansion
Number of subjects: 22
Study 30368373 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 22
Study 26885934 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-monitoring exercise intervention (SM condition)
Number of subjects: 13
Study 26885934 — intervention group
Group type: COMPARATOR
Intervention: Standard care exercise program (CON condition)
Number of subjects: 13
Study 25260762 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-media referrals
Number of subjects: 5008
Study 25260762 — intervention group
Group type: EXPERIMENTAL
Intervention: Paid-media referrals
Number of subjects: 5008
Study 25260762 — intervention group
Group type: EXPERIMENTAL
Intervention: Free-to-read print advertisements
Number of subjects: 5008
Study 25260762 — intervention group
Group type: COMPARATOR
Intervention: Fax recruits
Number of subjects: 5008
Study 25260762 — intervention group
Group type: COMPARATOR
Intervention: In-clinic recruits
Number of subjects: 5008
Study 22489903 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet plus moderate-to-high-intensity endurance training (MeDE)
Number of subjects: 45
Study 22489903 — intervention group
Group type: COMPARATOR
Intervention: Mediterranean diet (MeD)
Number of subjects: 45
Study 20351325 — intervention group
Group type: EXPERIMENTAL
Intervention: 80 IU/m(2) of pegylated arginine deiminase (ADI) weekly for up to 6 months
Number of subjects: 80
Study 20351325 — intervention group
Group type: EXPERIMENTAL
Intervention: 160 IU/m(2) of pegylated arginine deiminase (ADI) weekly for up to 6 months
Number of subjects: 80
Study 20351325 — intervention group
Group type: EXPERIMENTAL
Intervention: pegylated arginine deiminase (ADI)
Number of subjects: 80
Study 17506785 — intervention group
Group type: EXPERIMENTAL
Intervention: Dabigatran etexilate (10-400 mg single doses or 50-400 mg three times daily for 6 days)
Number of subjects: 40
Study 17506785 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 15474697 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin treatment started at least 3 days before the procedure
Number of subjects: 451
Study 15474697 — intervention group
Group type: COMPARATOR
Intervention: No treatment (Control group)
Number of subjects: 451
Study 11486456 — intervention group
Group type: EXPERIMENTAL
Intervention: 1% lanoconazole cream (Astat) monotherapy
Number of subjects: 0
Study 11486456 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy with 1% lanoconazole cream and 10% urea ointment (Pastaron)
Number of subjects: 0
Study 9743849 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 3 mg
Number of subjects: 100
Study 9743849 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 9 mg
Number of subjects: 100
Study 9743849 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol 27 mg
Number of subjects: 100
Study 9743849 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 7920872 — intervention group
Group type: EXPERIMENTAL
Intervention: WT4EE
Number of subjects: 118
Study 7920872 — intervention group
Group type: COMPARATOR
Intervention: C4EE
Number of subjects: 118
Study 2899062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 16-8714 (0.17 mg/kg fat free mass)
Number of subjects: 12
Study 2899062 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 2899062 — intervention group
Group type: EXPERIMENTAL
Intervention: Ro 16-8714
Number of subjects: 12
Study 27387513 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based exercise programme
Number of subjects: 63
Study 27387513 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 63
Study 27597276 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-102 (35mg/m²/dose twice daily)
Number of subjects: 18
Study 27597276 — intervention group
Group type: COMPARATOR
Intervention: Control (topotecan or amrubicin)
Number of subjects: 18
Study 25911121 — intervention group
Group type: EXPERIMENTAL
Intervention: IMF-screws (IMFS)
Number of subjects: 50
Study 25911121 — intervention group
Group type: COMPARATOR
Intervention: arch bars
Number of subjects: 50
Study 25911121 — intervention group
Group type: EXPERIMENTAL
Intervention: IMF-screws (IMFS) and arch bars
Number of subjects: 50
Study 24044216 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha‐2a combined with entecavir for 12 weeks, then Peginterferon alpha‐2a monotherapy for 36 weeks (Group C)
Number of subjects: 60
Study 24044216 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alpha‐2a monotherapy for 48 weeks (Group A)
Number of subjects: 60
Study 24044216 — intervention group
Group type: COMPARATOR
Intervention: Entecavir monotherapy for more than 48 weeks (Group B)
Number of subjects: 60
Study 24044216 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha‐2a combined with entecavir (Group C)
Number of subjects: 60
Study 20307262 — intervention group
Group type: EXPERIMENTAL
Intervention: SCION‐PAIN program (additional to standard pain treatment)
Number of subjects: 240
Study 20307262 — intervention group
Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 240
Study 17951035 — intervention group
Group type: EXPERIMENTAL
Intervention: HHQ-free coffee (zero-dose)
Number of subjects: 203
Study 17951035 — intervention group
Group type: EXPERIMENTAL
Intervention: HHQ-free coffee (low-dose)
Number of subjects: 203